400 Participants Needed

Mobile Health Rehabilitation for Heart Disease

(RESILIENT Trial)

Recruiting at 1 trial location
AF
SP
Overseen ByStephanie Pena
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: NYU Langone Health
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

RESILIENT is a phase II, multi-center, prospective, pragmatic randomized clinical trial with blinded assessment of the primary endpoint. This study aims to evaluate whether mHealth-CR improves functional capacity in older adults (age ≥65) with IHD compared with standard traditional cardiac rehabilitation care. A total of 400 eligible patients will be randomized in 3:1 manner to mHealth-CR versus usual care for assessment of primary endpoint. Enrollment will occur over approximately 42 months with an expected minimum of 3 months follow-up per participant.

Research Team

JD

John Dodson, MD

Principal Investigator

New York Langone Health

Eligibility Criteria

This trial is for older adults aged 65 or above who have been hospitalized for ischemic heart disease (like a heart attack, stent placement, or bypass surgery) recently. They must be able to walk, give consent themselves, and use mobile health technology in English or Spanish. People with severe movement disorders, very short life expectancy, severe cognitive issues, certain recent surgeries or conditions that limit walking are not eligible.

Inclusion Criteria

I can follow study instructions and perform tasks like a 6-minute walk test.
I am 65 years old or older.
I am currently in the hospital or was hospitalized in the last 2 weeks for a heart attack or heart surgery.
See 1 more

Exclusion Criteria

You have a left ventricular assist device.
The doctors think there are other safety concerns or you might not follow the study rules.
I have significant memory or thinking problems.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to either mHealth-CR or usual care for cardiac rehabilitation

3 months
Weekly virtual check-ins for mHealth-CR group

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months
1 visit (in-person) at 3 months

Long-term follow-up

Participants are monitored for hospital readmissions and mortality

1 year

Treatment Details

Interventions

  • mHealth-CR
Trial Overview The RESILIENT study tests if a mobile health cardiac rehab program (mHealth-CR) can improve the physical function of older adults after hospitalization due to heart disease better than standard care. Participants will either receive mHealth-CR or usual care in a ratio of 3:1 by random selection.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: mHealth-CRExperimental Treatment1 Intervention
Participants in this arm will receive the mHealth-CR intervention.
Group II: Usual CareActive Control1 Intervention
Participants in this arm receive usual care.

Find a Clinic Near You

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials
1,431
Recruited
838,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security